drugset
drugset / Trial / NCT06343064

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

NCT06343064 ↗

Phase 1/2 Recruiting 156 enrolled Avistone Biotechnology Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC

Timeline

Start
2023-06-13
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PLB1004 Small molecule 80 mg Oral
Subject PLB1004 Small molecule 160 mg Oral
Subject Vebreltinib Small molecule 100 mg Oral
Subject Vebreltinib Small molecule 150 mg Oral
Subject Vebreltinib Small molecule 200 mg Oral

Indications

non-small cell lung carcinoma